Skip to main content
OpenTrials
Completed

NCT Number: NCT03163628

biomArkers to differeNtiate bacTerial From vIral iNfEctions

ANTOINE is a prospective trial which aims to assess diagnostic performance of 7 biomarkers for the diagnosis of severe bacterial infections (SBI) in children aged from 7 days to 36 months.

Fever is a frequent cause of consultation in pediatric emergency departments. Clinical diagnostic tools are rare and discrimination between severe bacterial infection and viral infection is difficult to confidently state. The prevalence of severe bacterial infections (IBS) varies from 10 to 25% according to the studies. Biological markers such as procalcitonin (PCT) and C-reactive protein (CRP) are commonly used in clinical practice. These markers have bacterial specificity but share a wide range of values with viral infections and do not make it possible to exclude or to confirm definitively the diagnosis of IBS. The use of new markers to improve the diagnosis of bacterial and viral infections is increasingly studied in adults. The diagnostic value of these new markers has been demonstrated by associating their dosage with that of CRP for example. This is the case for IP-10, TRAIL or MxA. However, very few pediatric studies have been carried out to date on these new biomarkers. However, in pediatrics, these diagnostic tools based on the combination of biomarkers to discriminate against viral and bacterial infections could be a major help in the suspicions of IBS. 7 biomarkers were selected to be evaluated in this study. This study is designed to determine the best biomarkers combination for the SBI diagnosis on a cohort of 800 patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infection, Bacterial Bacterial Infections Bacterial Infections and Mycoses Disease Infection Viral Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Virus Diseases

Age range

7 day–36 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospices Civils de Lyon, Bron, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Febrile children:
  • Between 7 days and 3 months old : fever >38°C for more than 6 hours (late neonatal fever suspected) for which the physician prescribed venipuncture
  • Between 3 months and 36 months old : fever ≥38,5°C for more than 6 hours and less than 7 days for which the physician prescribed venipuncture for suspected severe bacterial infection
  • Patient with national health cover
  • Consent form signed by at least one parent

Exclusion criteria

  • Children treated by antibiotherapy within the past 48h
  • Children with congenital or acquired immunodeficiency syndrome or long-term immunosuppression treatment
  • Vaccinated children within 48h by an inactivated vaccine or within 10 days for the MMR vaccines
  • Children with a chronic disease
  • undergoing surgery within 7 days before inclusion

Treatment and study plan

Diagnostic performances of a combination of biomarkers

Biological

3 ml of blood will be drawn at inclusion at the same time of the venipuncture prescribed for standard care. The dosage of the 7 biomarkers will be performed in a central laboratory. The adjudication committee will classify patients in 6 groups, based on their clinical data. The committee will not be aware of the biological results. The analysis of Train Set data will aim to identify the most effective combination of markers in response to the primary objective of identifying biomarkers for the diagnosis of severe bacterial infections. The best combination selected will then be applied to the Test Set data (approximately the other half of patients), in order to obtain its real and unbiased performance.

The calculation of positive and negative likelihood ratios will be performed.

The targeted performances are:

  • A positive likelihood ratio (LR +) of 5.67 minimum, ideally greater than 8.5.
  • A negative likelihood ratio (LR-) of 0.5 maximum, ideally less than 0.3.

Primary outcomes

  1. Diagnosis of severe bacterial infection (SBI)

    Time frame: at Day 7

    Diagnostic performance of the biomarkers combination will be compared to the diagnostic performances of CRP alone and PCT alone, based on the adjudication committee classification (gold standard).

    The Adjudication Committee will sort patients in 6 different groups according to their clinical data: (1) proved SBI, (2) presumed SBI, (3) both viral & bacterial infection, (4) proved viral infection, (5) presumed viral infection, & (6) not classifiable patient. To answer the primary outcome, the SBI class will group proved SBI (1), presumed SBI (2) and both viral & bacterial infection (3).

Secondary outcomes

  1. Diagnosis of viral infection

    Time frame: at Day 7

    Diagnostic performance of the biomarkers combination will be compared to the diagnostic performances of CRP alone and PCT alone, based on the adjudication committee classification (gold standard).

    The Adjudication Committee will sort patients in 6 different groups according to their clinical data: (1) proved SBI, (2) presumed SBI, (3) both viral & bacterial infection, (4) proved viral infection, (5) presumed viral infection, & (6) not classifiable patient. To answer this secondary outcome, the SBI class will group (4) proved viral infection, (5) presumed viral infection.

  2. Unfavorable evolution

    Time frame: at Day 7

    Evaluate the possible association between biomarkers concentration and patient unfavorable evolution, defined as:

    • For hospitalized patient : entry in a health department with an higher level of care or death within 7 days after study inclusion
    • For non-hospitalized patient : hospitalization or death within 7 days after study inclusion

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Performance Assessment of 7 Biomarkers for the Diagnosis of Severe Bacterial Infections in Children Aged From 7 Days to 36 Months.

Acronym: ANTOINE

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
May 23, 2017
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.